StockIQpro
NASDAQ:PYXS

Pyxis Oncology, Inc.

Track all markets on TradingView
Track all markets on TradingView

Pyxis Oncology, Inc.'s revenue fell 14.2% in fiscal 2025 to $13.9M while operating margin fell to −609.2%. Free cash flow was −$63.5M, −458.3% of revenue, and the diluted share count rose 6.3%.Summary generated from Pyxis Oncology, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$13.9M
Revenue growth−14.2%
Revenue, 5-yr CAGRn/a
Gross margin82.8%
Operating margin−609.2%
Net margin−574.5%
ROICn/a
Return on equity−91.4%
Debt / equityn/a
Free cash flow−$63.5M
FCF margin−458.3%
Share count change+6.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/a1614
Operating income−70−123−82−89−84
Net income−76−121−74−77−80
Free cash flow−36−96−77−58−64

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations